Figure 2.
HDAC inhibition modulates histone acetylation. (A) levels of acetylated histone 3 (levels in each patient normalized to β-actin; ▲, n = 16; ▪, n = 10) and (B) levels of IL-6, (C) Reg3α, and (D) ST2 on day 30 post-HCT (●, n = 5; ▲, n = 36; ▪, n = 30). (▲) Patients in the study who received vorinostat. (▪) Control patients who did not receive vorinostat. (●) Healthy donors. Median values ± interquartile range are plotted. Each data point represents a single patient.

HDAC inhibition modulates histone acetylation. (A) levels of acetylated histone 3 (levels in each patient normalized to β-actin; ▲, n = 16; ▪, n = 10) and (B) levels of IL-6, (C) Reg3α, and (D) ST2 on day 30 post-HCT (●, n = 5; ▲, n = 36; ▪, n = 30). (▲) Patients in the study who received vorinostat. (▪) Control patients who did not receive vorinostat. (●) Healthy donors. Median values ± interquartile range are plotted. Each data point represents a single patient.

Close Modal

or Create an Account

Close Modal
Close Modal